|Bid||0.0000 x 4000|
|Ask||3.4600 x 4000|
|Day's Range||3.3000 - 3.4800|
|52 Week Range||3.0900 - 9.4800|
|Beta (3Y Monthly)||1.82|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.70|
ASSERTIO THERAPEUTICS has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Assertio Therapeutics Inc NASDAQ/NGS:ASRTView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate Bearish sentimentShort interest | PositiveShort interest is moderate for ASRT with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ASRT are favorable, with net inflows of $1.82 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Assertio (ASRT) delivered earnings and revenue surprises of 27.78% and 4.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Lake Forest, Illinois-based company said it had a loss of 22 cents. Earnings, adjusted for non-recurring costs and stock option expense, were 23 cents per share. The results topped ...
-- Reports Neurology Franchise Net Sales of $26.3 million -- -- Commercialization Agreement Revenues of $30.9 million -- -- Raises 2019 Earnings Guidance Range and Confirms.
During Assertio Therapeutics' (ASRT) Q1 conference call, investor focus will be on the company's progress with its neurology franchise and the NDA filing for cosyntropin.
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LAKE FOREST, Ill., April 24, 2019 -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release first quarter 2019 financial results on Wednesday, May 8,.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). To keep the lesson grounded in practicality, we...
Assertio Therapeutics, Inc. (ASRT) announced today that James (Jay) J. Galeota, Jr. has been appointed to the Company’s Board of Directors. Mr. Galeota most recently served as the President and Chief Operating Officer of G&W Laboratories, Inc. “We are thrilled to welcome Jay to our Board of Directors,” said Arthur Higgins, President and CEO of Assertio.
NEW YORK/BOSTON (Reuters) - U.S. healthcare plan and pharmacy benefits manager Magellan Health Inc is nearing an agreement with Starboard Value LP to expand the size of its board by several seats, including a representative from the activist hedge fund, three sources familiar with the matter said on Thursday. Starboard declined to comment. The hedge fund said that although the company operates in an industry that is poised for growth, it has underperformed because of operational missteps and poor capital allocation.
LAKE FOREST, Ill., March 28, 2019 -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that the United States Court of Appeals for the Federal Circuit has ruled in.
Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.
Assertio Therapeutics Inc (NASDAQ:ASRT) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.